StockDriftsStockDriftsTop 13 Gsk PLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR THERAPEUTICS AG | 29.17% | 3.22M | $175.7M | +0.00%(+0) | $58.62(-7.91%) | 2026-06-30 | |
| WVE | WAVE LIFE SCIENCES LTD | 17.6% | 18.25M | $106.0M | +0.00%(+0) | $12.16(-57.24%) | 2026-06-30 | |
| VIR | VIR BIOTECHNOLOGY INC | 14.47% | 8.55M | $87.1M | +0.00%(+0) | $5.87(+54.94%) | 2026-06-30 | |
| BNTX | BIONTECH SE | 13.75% | 889.8K | $82.8M | +0.00%(+0) | $96.91(-4.10%) | 2026-06-30 | |
| IDYA | IDEAYA BIOSCIENCES INC | 8.25% | 1.33M | $49.7M | +0.00%(+0) | $30.89(+18.74%) | 2026-06-30 | |
| CYTK | CYTOKINETICS INC | 4.82% | 340.4K | $29.0M | +0.00%(+0) | $59.25(+23.97%) | 2026-06-30 | |
| LYEL | LYELL IMMUNOPHARMA INC | 3.53% | 1.51M | $21.3M | +0.00%(+0) | $23.51(-40.37%) | 2026-06-30 | |
| SPRO | SPERO THERAPEUTICS INC | 3.37% | 9.19M | $20.3M | +0.00%(+0) | $2.10(-41.09%) | 2026-06-30 | |
| NKTX | NKARTA INC | 1.48% | 3.15M | $8.9M | +0.00%(+0) | $1.96(+17.35%) | 2026-06-30 | |
| FULC | FULCRUM THERAPEUTICS INC | 1.09% | 1.79M | $6.5M | +0.00%(+0) | $10.26(-63.82%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (2 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | -24.62% |
| Top 20 Holdings Unweighted | — | — | — | — | -9.21% |
Gsk PLC reports $602.22M in US-listed equity holdings across 13 positions in its most recent 13F filing. Its largest disclosed positions are CRSP (29.2%), WVE (17.6%) and VIR (14.5%). The top 20 holdings account for 100.01% of reported assets. Its disclosed equity book has returned -24.62% cumulatively over 2 quarters. Figures reflect the Q2 2026 filing.
Sign up free to track Gsk PLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Gsk PLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1131399). View Gsk PLC’s 13F filings on SEC